











treat substance use disorders. *Int Rev Neurobiol* 126, 2016, 263-91.

[5] Alving CR, Matyas GR, Torres O et al. Adjuvants for vaccines to drugs of abuse and addiction. *Vaccine* 32(42), 2014, 5382-9.

[6] Orson FM, Wang R, Brimijoin S et al. The future potential for cocaine vaccines. *Expert Opin Biol Ther* 14(9), 2014, 1271-83.

[7] Kosten TR, Domingo CB. Can you vaccinate against substance abuse? *Expert Opin Biol Ther* 13(8), 2013, 1093-7.

[8] Kosten TR, Domingo CB, Shorter D et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. *Drug Alcohol Depend* 140, 2014, 42-7.

[9] Orson FM, Rossen RD, Shen X et al. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. *Am J Addict* 22(2), 2013, 169-74.

[10] Nielsen DA, Hamon SC, Kosten TR. The k-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. *Psychiatr Genet* 23(6), 2013, 225-32.

[11] Martell BA, Orson FM, Poling J et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. *Arch Gen Psychiatry* 66(10), 2009, 1116-23.

[12] Martell BA, Mitchell E, Poling J et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. *Biol Psychiatry* 58(2), 2005, 158-64.

[13] Kosten TR, Rosen M, Bond J et al. Human therapeutic cocaine vaccine: safety and immunogenicity. *Vaccine* 20(7-8), 2002, 1196-204.

[14] Havermans A, Vuurman EF, van der Hurk J et al. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. *Addiction* 109(8), 2014, 1260-7.

[15] Hoogsteder PH, Kotz D, van Spiegel PI et al. Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. *Addiction* 109(8), 2014, 1252-9.

[16] Hoogsteder PH, Kotz D, van Spiegel PI et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double-blind, randomized, placebo-controlled trial. *BMC Public Health* 12, 2012, 1052.

[17] Tonstad S, heggen E, Giljam H et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicentre clinical trial. *Nicotine Tob Res* 15(9), 2013, 1492-501.

[18] Hatsukami DK, Jorenby DE, Gonzales D et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. *Clin Pharmacol Ther* 89(3), 2011, 392-9.

[19] Comuz J, Zwahlen S, jungi WF et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. *PLoS One* 3(6), 2008, e2547.

[20] Wagena EJ, de Vos A, Horwith G, van Schayck CP. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. *Nicotine Tob Res* 10(1), 2008, 213-8.

[21] Hatsukami DK, Rennard S, Jorenby D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. *Clin Pharmacol Ther* 78(5), 2005, 456-67.

[22] Stevens MW, Gunnell MG, Tawney R, Owens SM. Optimization of a methamphetamine conjugate vaccine for antibody production in mice. *Int Immunopharmacol* 35, 2016, 137-41.

[23] Kimishima A, Wenthur CJ, Zhou B, Janda KD. An advance in prescription opioid vaccines: Overdose mortality reduction and extraordinary alteration of drug half-life. *ACS Chem Biol* 12(1), 2017, 36-40.

[24] Bremer PT, Kimishima A, Schlosburg JE et al. Combating synthetic designer opioids: A conjugate vaccine ablates lethal doses of fentanyl class drugs. *Angew Chem Int Ed Engl* 55(11), 2016, 3772-5.